Three briefs, one throughline: biological aging clocks stopped being a curiosity and started getting interrogated — reviewed by the field's most-cited names, tracked longitudinally instead of once, and tested against real interventions from semaglutide to yogurt-and-exercise. Meanwhile the immune system had an unusually good week, with the thymus rehabilitated from vestigial organ to mortality predictor and a stem-cell mechanism explaining how inflammation goes chronic with age. The bottom line: aging is increasingly treated as something you can measure with precision and occasionally nudge — the measuring got much better this week; the nudging remains early, scattered, and mostly in mice.
Data presented at AAIC 2026 showed a patient-administered autoinjector version of the Alzheimer's drug lecanemab produced equivalent drug exposure, amyloid clearance, and safety compared with intravenous infusion.
Tony Wyss-Coray and Eric Topol reviewed methylation, proteomic, transcriptomic, and organ-specific aging clocks in Nature Medicine, assessing what they actually predict about disease risk and how well they respond to interventions.
A randomized, placebo-controlled trial in adults with HIV-associated lipohypertrophy found semaglutide lowered biological age across several epigenetic clocks; a smaller pilot in a metabolic liver disease cohort found the same pattern.
Two companion Nature Aging papers used spatial transcriptomics to locate a senescent, disease-associated microglial population concentrated in aged mouse brain white matter, then showed senolytic treatment reduced it.
Two Mass General Brigham papers in Nature found that AI-scored thymic health from routine CT scans tracked with 50% lower all-cause mortality, 63% lower cardiovascular death, and 36% lower lung cancer risk.
A Nature Aging study found SIRT3 normally restrains an overzealous form of trained immunity in aging hematopoietic stem cells; without it, the cells overreact and drive chronic inflammation.
SIRT6 variants enriched in centenarians were shown to enhance DNA repair and suppress transposable element activity, lowering cellular senescence burden.
In more than 27,000 UK Biobank adults, brain-imaging age gaps scaled with the number of metabolic syndrome components present, reaching roughly 2.3 years of extra apparent brain age in people with all five.
A study of nursing home residents found recombinant zoster vaccine recipients had a 24% lower relative risk of dementia over four years of follow-up.
Kuo et al. found that measuring epigenetic age at multiple time points substantially improved mortality risk prediction in 699 European adults, with faster clock acceleration robustly linked to earlier death.
One email a week. The ten things in AI that mattered, and why. Choose your channel.